Filtered By:
Specialty: Neurology
Drug: Pradaxa
This page shows you your search results in order of date. This is page number 4.
Order by Relevance | Date
Total 127 results found since Jan 2013.
Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack Clinical Sciences
Conclusions—Results from our study of the 3 NOACs versus warfarin in nonvalvular atrial fibrillation patients with a previous history of stroke/transient ischemic attack are relatively consistent with their respective phase III trials and previous stroke/transient ischemic attack subgroup analyses. All NOACs seemed no worse than warfarin in respect to ischemic stroke, ICH, or major bleeding risk.
Source: Stroke - July 24, 2017 Category: Neurology Authors: Craig I. Coleman, W. Frank Peacock, Thomas J. Bunz, Mark J. Alberts Tags: Arrhythmias, Quality and Outcomes, Intracranial Hemorrhage, Ischemic Stroke Original Contributions Source Type: research
Cerebral Microbleeds in Murine Amyloid Angiopathy Basic Sciences
Conclusions—Anticoagulation with warfarin or dabigatran for 3 to 4 months does not promote the formation of CMBs in aged APP23 mice. Nevertheless, warfarin but not dabigatran is associated with a higher risk of extensive intracerebral hemorrhage, suggesting that this model may allow preclinical safety evaluation of antithrombotic therapies.
Source: Stroke - July 24, 2017 Category: Neurology Authors: Marilena Marinescu, Li Sun, Marc Fatar, Andreas Neubauer, Lothar Schad, Joanne van Ryn, Lorenz Lehmann, Roland Veltkamp Tags: Animal Models of Human Disease, Basic Science Research, Translational Studies Original Contributions Source Type: research
Thrombocytopenia induced by dabigatran: two case reports
Vitamin K inhibitors (e.g. warfarin) and indirect thrombin inhibitors (e.g. heparin) are widely used to prevent thromboembolic disorders (e.g. myocardial infarction, venous thromboembolism, and stroke). These ...
Source: BMC Neurology - June 29, 2017 Category: Neurology Authors: Hyun Goo Kang, Seung Jae Lee, Ji Yeon Chung and Jin Sung Cheong Source Type: research
Severe Vasospasm of the Middle Cerebral Artery after Mechanical Thrombectomy Due to Infective Endocarditis: An Autopsy Case
We describe a case of middle cerebral artery occlusion due to IE, which caused severe vasospasm and reocclusion after mechanical thrombectomy (MT). We present the pathologic findings of the occluded middle cerebral artery and investigate the precautions to be taken while performing MT due to IE. A 72-year-old man with atrial fibrillation treated with dabigatran presented with right hemiparesis and aphasia.
Source: Journal of Stroke and Cerebrovascular Diseases - June 29, 2017 Category: Neurology Authors: Wataru Nishino, Yosuke Tajima, Toru Inoue, Michihiro Hayasaka, Bi Katsu, Koichi Ebihara, Daisuke Kawauchi, Masaaki Kubota, Sumio Suda Tags: Case Studies Source Type: research
Intravenous Fibrinolysis in Ischemic Stroke of Large Vessel after Reversing Effect of Dabigatran with Idarucizumab
We present our experience regarding the use of intravenous tissue plasminogen activator in a patient with ischemic stroke due to complete occlusion of the left middle cerebral artery after blocking the effect of dabigatran with idarucizumab and whose result was an almost total improvement of the neurologic deficit.
Source: Journal of Stroke and Cerebrovascular Diseases - June 26, 2017 Category: Neurology Authors: Gary Alvarez Bravo, Emilio Orts Castro, Guilherme Carvalho Monteiro, Ignacio L ópez Zuazo Tags: Case Studies Source Type: research
Letter by Machado-Alba et al Regarding Article, “Rivaroxaban Versus Dabigatran or Warfarin in Real-World Studies of Stroke Prevention in Atrial Fibrillation: Systematic Review and Meta-Analysis” Letter to the Editor
Source: Stroke - May 22, 2017 Category: Neurology Authors: Jorge Enrique Machado–Alba, Daniel Ricardo Arias–Jaramillo, Andres Gaviria–Mendoza Tags: Epidemiology, Primary Prevention, Risk Factors, Secondary Prevention Letters to the Editor Source Type: research
Response by Bai et al to Letter Regarding Article, “Rivaroxaban Versus Dabigatran or Warfarin in Real-World Studies of Stroke Prevention in Atrial Fibrillation: Systematic Review and Meta-Analysis” Letter to the Editor
Source: Stroke - May 22, 2017 Category: Neurology Authors: Ying Bai, Alena Shantsila, Gregory Y.H. Lip Tags: Arrhythmias Letters to the Editor Source Type: research
Systemic Thrombolysis in Acute Ischemic Stroke after Dabigatran Etexilate Reversal with Idarucizumab —A Case Report
Idarucizumab is a reversal agent for dabigatran etexilate. By reversing the anticoagulating effect of dabigatran etexilate with idarucizumab (Praxbind), patients presenting with an acute ischemic stroke can now be eligible for thrombolysis.
Source: Journal of Stroke and Cerebrovascular Diseases - May 4, 2017 Category: Neurology Authors: Derya Tireli, Jun He, Mette Maria Nordling, Troels Wienecke Tags: Case Studies Source Type: research
Intravenous Thrombolysis in Anticoagulated and Thrombocytopenic Ischemic Stroke Patients Does Not Increase the Risk of Intracerebral Hemorrhage (P4.271)
Conclusions:These data suggest that IV rt-PA can be safely administered in coagulopathic and thrombocytopenic patients. Although rates of sICH and mortality were similar to the NINDS cohort, caution may be needed to identify certain hemorrhagic risk factors. Routine exclusion of anticoagulated or thrombocytopenic patients is not supported and the use of IV rt-PA in these patients may increase the eligibility for acute stroke therapy, particularly at institutions where IA therapy is unavailable.Disclosure: Dr. Barazangi has received personal compensation for activities with Genentech. Dr. Sorensen has nothing to disclose. D...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Barazangi, N., Sorensen, S., Chen, C., Wong, C., Yee, A., Ke, M., Rose, J., Grosvenor, D., Bedenk, A., Fernandes, J., Tong, D. Tags: Thrombolysis and Acute Evaluation in Ischemic Stroke Source Type: research
Difference of Clinical Condition of Ischemic Stroke between Warfarin and Direct Oral Anticoagulants (P6.285)
Conclusions:Ischemic lesion size may be smaller in DOACs compared with warfarin. There is a possibility that direct thrombin inhibitor may provide better outcome compared with other anticoagulants. Larger prospective study should be conducted to confirm these findings.Disclosure: Dr. Nakase has nothing to disclose. Dr. Moroi has nothing to disclose. Dr. Ishikawa has nothing to disclose.
Source: Neurology - April 17, 2017 Category: Neurology Authors: Nakase, T., Moroi, J., Ishikawa, T. Tags: Prevention of Cerebrovascular Disease Source Type: research
Successful Treatment with t-PA of a Stroke Patient after Reversal of Dabigatran with Idarucizumab (P3.291)
Conclusions:We report the first successful treatment with t-PA of an acute stroke patient after reversal of dabigatran with idarucizumab.Disclosure: Dr. Cossey has nothing to disclose. Dr. Reddy has nothing to disclose. Dr. Savitz has received research support from the NIH. Dr. Grotta has received personal compensation for activities with Frazer and Stryker. Dr. Grotta has received research support from Genentech and Medtronic.
Source: Neurology - April 17, 2017 Category: Neurology Authors: Cossey, T., Reddy, S., Savitz, S., Grotta, J. Tags: Cerebrovascular Disease Case Reports II Source Type: research
Acute Stroke Despite Dabigatran Anticoagulation Treated with Idarucizumab and Intravenous Tissue Plasminogen Activator
Dabigatran is a direct thrombin inhibitor used to reduce the risk of stroke in patients with nonvalvular atrial fibrillation. For patients who present with an acute stroke despite dabigatran therapy, clinical data on the use of intravenous tissue plasminogen activator (IV-tPA) is limited. There is an anticipated increased risk of symptomatic intracranial hemorrhage (sICH) when using IV-tPA in patients on dabigatran therapy. In 2015, the humanized monoclonal antibody fragment idarucizumab was approved for rapid (minutes) reversal of anticoagulant effects of dabigatran.
Source: Journal of Stroke and Cerebrovascular Diseases - April 14, 2017 Category: Neurology Authors: David Bissig, Rashmi Manjunath, Brittany R. Traylor, David P. Richman, Kwan L. Ng Tags: Case Studies Source Type: research
Rivaroxaban Versus Dabigatran or Warfarin in Real-World Studies of Stroke Prevention in Atrial Fibrillation Clinical Sciences
Conclusions—In this systematic review and meta-analysis, rivaroxaban was as effective as dabigatran, but was more effective than warfarin for the prevention of stroke/thromboembolism in atrial fibrillation patients. Major bleeding risk was significantly higher with rivaroxaban than with dabigatran, as was all-cause mortality and gastrointestinal bleeding. Rivaroxaban was comparable to warfarin for major bleeding, with an increased risk in gastrointestinal bleeding and decreased risk of intracranial hemorrhage.
Source: Stroke - March 27, 2017 Category: Neurology Authors: Ying Bai, Hai Deng, Alena Shantsila, Gregory Y.H. Lip Tags: Meta Analysis, Quality and Outcomes Original Contributions Source Type: research
Comparison of the cost-utility of direct oral anticoagulants for the prevention of stroke in patients with atrial fibrillation in Spain.
CONCLUSIONS: All three direct anticoagulants are cost-effective against acenocoumarol. Dabigatran is economically dominant over rivaroxaban and apixaban in the Spanish setting, as it is more effective and cheaper.
PMID: 28272725 [PubMed - in process]
Source: Revista de Neurologia - March 9, 2017 Category: Neurology Authors: Monreal-Bosch M, Soulard S, Crespo C, Brand S, Kansal A Tags: Rev Neurol Source Type: research
Adverse clinical outcomes after dabigatran reversal with idarucizumab to facilitate acute stroke thrombolysis
Source: Journal of Neurology - February 5, 2017 Category: Neurology Source Type: research
